Cancer Institute A national cancer institute
designated cancer center
Profile http://med.stanford.edu/profiles/cancer/researcher/Judith_Shizuru/
Email this profile
Portrait View Larger

Judith Shizuru

Academic Appointments

  • Associate Professor of Medicine (Blood and Marrow Transplantation)

Key Documents

Contact Information

  • Clinical Offices
    Blood and Marrow Transplant Clinic 875 Blake Wilbur Dr Clinic F MC 5826 Stanford, CA 94305
    Tel Work (650) 723-0822 Fax (650) 498-6159
  • Academic Offices
    Personal Information
    Email Tel (650) 723-0822
    Administrative Contact
    Sara Clark Administrative Associate Tel Work 650-725-4959
    Not for medical emergencies or patient use

Professional Overview

Clinical Focus

  • Cancer> Blood and Marrow Transplant
  • Blood and Marrow Transplantation
  • Hematology

Honors and Awards

  • Scholar Award, Amy Strelzer Manasevit (2001)
  • Junior Faculty Scholars Award, Howard Hughes Medical Institute (1996-2000)
  • Career Award in the Biomedical Sciences, Burroughs Wellcome Fund (1996-2000)
  • Excellence in Research in the Field of Hematopoiesis, Cheryl Whitlock Award (1996)
  • Postdoctoral Fellowship, Juvenile Diabetes Foundation (1991-1993)
  • Postdoctoral Fellowship, Juvenile Diabetes Foundation (1989-1991)
View All 7honors and awards of Judith Shizuru

Professional Education

Internship: UCSF Medical Center CA (1993)
Residency: UCSF Medical Center CA (1994)
Fellowship: Stanford University Medical Center CA (1997)
Medical Education: Stanford University School of Medicine CA (1992)

Courses

2014-15

Postdoctoral Advisees

Akanksha ChhabraHeather Guerston

Scientific Focus

Current Research and Scholarly Interests

The research interests are to understand the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow (BM) cells and to understand the way in which BM grafts modify immune responses. This research complements our interest in clinical BM transplantation and aspects of these studies are aimed at solving some of the major problems of BM transplantation which include graft-vs-host disease and BM engraftment failure. Conventional BM transplantation involves the transfer of heterogeneous populations of cells composed of rare hematopoietic stem cells (HSCs) and differentiated blood cell types. To study these issues our approach has been to transplant phenotypically purified cells under defined conditions. The specific projects in my laboratory include:

1) Identification of the cells and molecules responsible for resistance to engraftment of purified allogeneic HSCs. We and others have shown that cells with NK determinants constitute a significant barrier to allogeneic HSC engraftment, and that transplanted whole BM contains a population that facilitates engraftment. In these experiments our approach to identify the cell population(s) and mechanism by which HSC engraftment is resisted is to use recipient mice from strains that lack defined immune functions. We are studying the cells in BM and spleen that are bound and/or depleted by a-ASGMI, and in this way identify the candidate barrier populations.

2) Use of transplants of purified HSCs to induce tolerance to allo- and autoantigens, and study of the mechanisms by which such tolerance is induced. We continue to develop preclinical models for organ tolerance induction and treatment of autoimmune disease by using cell specific therapy. One goal is to decrease the morbidity of the recipient preparative regimen and to determine the lowest level of chimerism needed to induce immune tolerance. We propose to test donor/host strain combinations most relevant to human disease, including minor mismatched and haploidentical grafts.

3) Identification of the cells and molecules that confer graft vs leukemia/lymphoma (GVL) effects. We have developed a model of B cell lymphoma relapse after HSC transplant. To date our studies show that while purified allogeneic HSCs have no GVL activity, a population of BM cells that express CD3 and CD8 have significant GVL activity, and do not cause GVHD at the cell doses administered.

Publications

Publication tag cloud

Publication Topics

View All 112

Stanford Medicine Resources:

Footer Links: